[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368193-105":59,"doc-detail-368193-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","construction-of-an-anaplastic-thyroid-cancer-stratication-signature-to-guide-immune-therapy-selection-and-validation-of-the-pivotal-gene-hlf-through-in-vitro-experiments","Construction of an anaplastic thyroid cancer stratiﬁcation signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments","","Anaplastic thyroid carcinoma (ATC) remains highly aggressive with a median survival of about five months, and standard treatments provide limited benefit. This study builds a machine-learning model using gene expression and clinical data from TCGA, GEO, and a local cohort, alongside in vitro validation experiments. Five uniquely expressed genes stratify ATC into three groups with distinct responses to anti-PD1 therapy, supported by consensus clustering and WGCNA-derived findings. A refined anti-PD1 immune responsiveness signature was validated across thyroid cohorts and multiple melanoma clinical-trial cohorts, highlighting HLF as a key gene. Functional assays indicate HLF suppresses ATC progression by modulating EMT, reducing T-cell exhaustion, and increasing sorafenib sensitivity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/construction-of-an-anaplastic-thyroid-cancer-stratication-signature-to-guide-immune-therapy-selection-and-validation-of-the-pivotal-gene-hlf-through-in-vitro-experiments/368193/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/construction-of-an-anaplastic-thyroid-cancer-stratication-signature-to-guide-immune-therapy-selection-and-validation-of-the-pivotal-gene-hlf-through-in-vitro-experiments/368193.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in anaplastic thyroid carcinoma (ATC)?","Question",{"text":112,"@type":113},"ATC has a very poor prognosis and limited effectiveness of conventional therapies. The study targets the need to identify which patients may benefit from immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were immune-therapy responsive ATC subgroups identified?",{"text":117,"@type":113},"The researchers developed a machine-learning model from five genes, then used consensus clustering to divide ATC into three distinct groups with significantly different responses to anti-PD1 therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the role of the gene HLF in the proposed immune signature?",{"text":121,"@type":113},"HLF strongly associates with multiple cancer hallmarks and is highlighted as a pivotal gene within the refined signature for predicting immune responsiveness to anti-PD1 therapy.",{"name":123,"@type":110,"acceptedAnswer":124},"What in vitro evidence supports the biological effect of HLF?",{"text":125,"@type":113},"In vitro experiments show that HLF impedes ATC progression by downregulating EMT, reducing T-cell exhaustion, and increasing sensitivity to sorafenib.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368193,1790219094,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 13 January 2025  \nDOI 10.3389/fimmu.2024.1478904  \nOPEN ACCESS  \nEDITED BY  \nTakaji Matsutani, Maruho, Japan  \nREVIEWED BY  \nShivam Priya,  \nThe Ohio State University, United States Dmitry Aleksandrovich Zinovkin, Gomel State Medical University, Belarus Javier Ismael Altamirano Garca,  \nNational Institute of Cancerology (INCAN), Mexico  \n*CORRESPONDENCE  \nHuang Yuqing  \n [doctorark@163.com](doctorark@163.com)[ ](doctorark@163.com)Jin Haigang  \n[jhgwzxshp@163.com](jhgwzxshp@163.com)[ ](jhgwzxshp@163.com)Wang Shaowen  \n [Shawnwang1994@link.cuhk.edu.hk](Shawnwang1994@link.cuhk.edu.hk)  \n†These authors have contributed equally to this work  \nRECEIVED 11 August 2024  \nACCEPTED 24 December 2024  \nPUBLISHED 13 January 2025  \nCITATION  \nPengping L, Kexin Y, Yuwei X, Ke S, Rongguo L, Zhenyu W, Haigang J, Shaowen W and Yuqing H (2025)  \nConstruction of an anaplastic thyroid cancer stratiﬁcation signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments.  \nFront. Immunol. 15:1478904 .  \ndoi: 10.3389/fimmu.2024.1478904  \nCOPYRIGHT  \n© 2025 Pengping, Kexin, Yuwei, Ke, Rongguo, Zhenyu, Haigang, Shaowen and Yuqing. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nConstruction of an anaplastic thyroid cancer stratiﬁcation signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments  \nLi Pengping 1†, Yin Kexin 1†, Xie Yuwei 2†, Sun Ke 1, Li Rongguo 1, Wang Zhenyu 1, Jin Haigang 1*, Wang Shaowen 3* and Huang Yuqing 1*  \n1 Department of Thyroid & Breast Surgery, The First People’s Hospital of Xiaoshan District, Xiaoshan Afﬁliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang, China, 2The First Afﬁliated Hospital of Anhui Medical University, Hefei, Anhui, China, 3 Neuromedicine Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China  \nIntroduction: While most thyroid cancer patients have a favorable prognosis, anaplastic thyroid carcinoma (ATC) remains a particularly aggressive form with a median survival time of just ﬁve months. Conventional therapies offer limited beneﬁts for this type of thyroid cancer. Our study aims to identify ATC patients who might bene t from immunotherapy.  \nMethods: Our study uses multiple algorithms by R4 .2. 0, and gene expression and clinical data are collected from TCGA, GEO and local cohort. In vitro experiments, such as western blot and immunoﬂuorescence staining, are performed.  \nResults: Using a set of ﬁve genes uniquely expressed across various types of thyroid cancer, we developed a machine-learning model to distinguish each type within the GEO dataset of thyroid cancer patients (GSE60542, GSE76039, GSE33630, GSE53157, GSE65144, GSE29265, GSE82208, GSE27155, GSE58545, GSE54958, and GSE32662) . These genes allowed us to stratify ATC into three distinct groups, each exhibiting signiﬁcantly different responses to anti-PD1 therapy as determined by consensus clustering. Through weighted gene co-expression network analysis (WGCNA), weidentiﬁed 12 differentially expressed genes closely associated with immunotherapy outcomes. This led to the creation of a reﬁned signature for predicting ATC ’s immune responsiveness to anti-PD1 therapy, which was further validated using thyroid cancer cohorts from TCGA and nine melanoma cohorts from clinical trials. Among the 12 genes, HLF stood out due to its strong association with various cancer hallmarks.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nDiscussion: Our study revealed that HLF imped","cbCaidgziErr5OaN","https://ap.wps.com/l/cbCaidgziErr5OaN","pdf",19257869,15,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What problem does the study address in anaplastic thyroid carcinoma (ATC)?\",\"answer\":\"ATC has a very poor prognosis and limited effectiveness of conventional therapies. The study targets the need to identify which patients may benefit from immunotherapy.\"},{\"question\":\"How were immune-therapy responsive ATC subgroups identified?\",\"answer\":\"The researchers developed a machine-learning model from five genes, then used consensus clustering to divide ATC into three distinct groups with significantly different responses to anti-PD1 therapy.\"},{\"question\":\"What is the role of the gene HLF in the proposed immune signature?\",\"answer\":\"HLF strongly associates with multiple cancer hallmarks and is highlighted as a pivotal gene within the refined signature for predicting immune responsiveness to anti-PD1 therapy.\"},{\"question\":\"What in vitro evidence supports the biological effect of HLF?\",\"answer\":\"In vitro experiments show that HLF impedes ATC progression by downregulating EMT, reducing T-cell exhaustion, and increasing sensitivity to sorafenib.\"}]","Construction of an anaplastic thyroid cancer stratiﬁcation signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments | PDF",1790175530,38,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eff20239316e87119d210a4717fba12d.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79c42ba2585e808bfb4fa38151c0a8be.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfd7f5a6138898daf0d2531135c4c903.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcd3768477adec13975c1788932f3378.webp",980,1385]